Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients – ROC Analysis
The aim of the study was to identify new non-invasive ovarian cancer (OC) tumor markers. In postmenopausal ovarian cancer patients and in a control group (benign ovarian lesions and healthy subjects), preoperative plasma levels of cytokines, metalloproteinases and their tissue inhibitors were determ...
Saved in:
Published in | Anticancer research Vol. 39; no. 5; pp. 2575 - 2582 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Greece
International Institute of Anticancer Research
01.05.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 0250-7005 1791-7530 1791-7530 |
DOI | 10.21873/anticanres.13380 |
Cover
Summary: | The aim of the study was to identify new non-invasive ovarian cancer (OC) tumor markers.
In postmenopausal ovarian cancer patients and in a control group (benign ovarian lesions and healthy subjects), preoperative plasma levels of cytokines, metalloproteinases and their tissue inhibitors were determined using ELISA while those of CA125 and HE4 by chemiluminescent microparticle immunoassay methods.
The diagnostic sensitivity (SE) value was the highest for HE4 and MMP-7 (78.0%). The diagnostic specificity (SP) for M-CSF, VEGF and MMP-9 was 95.2%, 95.2% and 95.7%, respectively. The highest positive predictive value (PPV) for M-CSF and MMP-9 was ~84.6% and negative predictive value (NPV) for MMP-7 and HE4 was ~87.6%. The biggest areas under the ROC curve were obtained for the combination of VEGF, MMP-7 or MMP-9 with HE4+CA125 (0.9130-0.9234), but not for CA125+HE4 (0.8260).
Our research confirms the validity of combining classic markers with new markers to improve the diagnostic power of CA125 and HE4. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0250-7005 1791-7530 1791-7530 |
DOI: | 10.21873/anticanres.13380 |